Norwood Hospital

The investigation of jet energy loss in high-energy proton-proton (pp) collisions offers crucial insights into the properties of Quark-Gluon Plasma (QGP) and strongly interacting matter. In this study, we simulate 10,000 pp collision events using the Pythia event generator, followed by jet clustering via the longitudinally invariant anti-k_t algorithm implemented in Fastjet. The analysis focuses on examining missing transverse momentum (MET) and jet momentum imbalances to identify a mechanisms behind the potential energy loss on an event-by-event basis. Our results reveal a significant correlation between large MET values and low p_T2/p_T1 ratios, indicative of pronounced momentum imbalance between the leading and sub-leading jets. These findings suggest a substantial jet energy loss. Which is likely due to the medium interactions with implications for studying jet quenching phenomena in QGP. This work introduces a refined methodology for assessing jet quenching at a level of individual events, providing a detailed characterization of jet-medium interactions and contributing to the broader understanding of energy loss in high-energy nuclear collisions.

Natural killer (NK) cell homeostasis and effector functions require context-dependent signaling via numerous receptors, including the interleukin-15 receptor (IL-15R). Post-translational modifications can regulate receptor signaling, impacting receptor turnover and trafficking. Core fucosylation is one such modification known to impact receptor expression and is uniquely mediated by fucosyltransferase 8 (FUT8). We identified FUT8 as an essential gene required for IL-15R responsiveness in a human NK cell genome-wide CRISPR screen. To further validate core fucosylation in IL-15R signaling and NK cell biology, mice lacking Fut8 in NK cells (Fut8fl/flNcr1cre/+) were generated. The loss of core fucose in murine NK cells resulted in severe NK cell lymphopenia, with a reduction in IL-15Rβ (IL-2RB/CD122) expression, impairing in vivo homeostatic proliferation. The loss of FUT8 also decreased NK cell cytotoxicity, tumor immunity, and early viral immunity. Taking these results together, we have identified FUT8 as a key modulator of NK cell biology by regulating their development, IL-15R expression, and signaling.

To assess the cross-sectional and longitudinal associations of smoking behaviour with central arterial haemodynamic measures in samples of the Framingham Heart Study. In 6597 participants [3606 (55%) women, 51.5% never smoked, 34.8% formerly quit, 4.3% recently quit, and 9.3% currently smoking], we assessed relations of smoking behaviour with central arterial measures using multivariable linear regression models. In cross-sectional models, central arterial measures were different across smoking behaviour groups. Particularly, augmentation index (AI) was higher among participants who formerly quit smoking (least squares mean ± standard error = 14.1 ± 0.4%; P < 0.001) and were currently smoking (18.1 ± 0.5%; P < 0.001) compared with participants who never smoked (12.6 ± 0.3%). Among participants currently smoking, higher cigarettes per day [B = 1.41; 95% confidence interval (CI), 0.47-2.34] were associated with higher AI. Among participants who had quit smoking, higher pack-years were associated with higher AI (B = 0.85; 95% CI, 0.60-1.14) and central pulse pressure (B = 0.84; 95% CI, 0.46-1.21). Using restricted cubic splines, we observed a negative linear association for AI, but non-linear associations for characteristic impedance and central pulse pressure, with higher time since quit (all P < 0.001). Additionally, we observed non-linear patterns of central arterial measures with smoking cessation by smoking burden (<20 vs. ≥20 pack-years). In longitudinal models, we observed higher increases in AI among participants who persistently quit (4.62 ± 0.41%; P < 0.001) and persistently smoked (5.48 ± 0.70%; P = 0.002) compared with participants who never smoked (3.45 ± 0.37%). Central arterial measures are sensitive to differences and changes in smoking behaviour. Longer cessation may revert central arterial measures to levels observed with lower smoking exposure.

[[abstract]]The original scale for pulsatile power in Fig. 1 of this article is inaccurate. The figure should have been presented as depicted below.

The association of the American Heart Association's updated cardiovascular health score, the Life's Essential 8 (LE8), with cardiovascular disease (CVD) and death is not described in the FHS (Framingham Heart Study). We evaluated Framingham Offspring participants at examinations 2 and 6 (n=2888 and 1667; and mean age, 44 and 57 years, respectively), free of CVD with information on LE8 components. Using age-sex-adjusted Cox models, we related LE8 and its change (examination 2 to examination 6) with CVD and death risk and compared associations with those of the Life's Simple 7 score. Mean LE8 score at examination 2 was 67 points (minimum, 26 points; maximum, 100 points). At both examinations, participants were reclassified to a different cardiovascular health status, depending on which method (LE8 versus Life's Simple 7) was used (60% of participants in ideal Life's Simple 7 status were in intermediate LE8 category). On follow-up after examination 2 (median, 30 and 33 years for CVD and death, respectively), we observed 966 CVD events, and 1195 participants died. Participants having LE8≥68 (sample median) were at lower CVD and death risk compared with those with LE8<68 (examination 2: CVD hazard ratio [HR], 0.47 [95% CI, 0.41-0.54]; death HR, 0.55 [95% CI, 0.49-0.62]; all P<0.001). Participants maintaining low LE8 scores during life course were at highest CVD and death risk (CVD: HRs ranging from 1.8 to 2.3; P<0.001; death HR, 1.45 [95% CI, 1.13-1.85]; P=0.003 versus high-high group). Further studies are warranted to elucidate whether the LE8 score is a better marker of CVD and death risk, compared with Life's Simple 7 score.

With less than one percent of systemically injected nanoparticles accumulating in tumors, several novel approaches have been spurred to direct and release the therapy in or near tumors. One such approach depends on the acidic pH of the extracellular matrix and endosomes of the tumor. With an average pH of 6.8, the extracellular tumor matrix provides a gradient for pH-responsive particles to accumulate, enabling greater specificity. Upon uptake by tumor cells, nanoparticles are further exposed to lower pHs, reaching a pH of 5 in late endosomes. Based on these two acidic environments in the tumor, various pH-dependent targeting strategies have been employed to release chemotherapy or the combination of chemotherapy and nucleic acids from macromolecules such as the keratin protein or polymeric nanoparticles. We will review these release strategies, including pH-sensitive linkages between the carrier and hydrophobic chemotherapy agent, the protonation and disruption of polymeric nanoparticles, an amalgam of these first two approaches, and the release of polymers shielding drug-loaded nanoparticles. While several pH-sensitive strategies have demonstrated marked antitumor efficacy in preclinical trials, many studies are early in their development with several obstacles that may limit their clinical use.